Share
 
Title
Code
Session Type
Channel
Date Time
Chair:

This session is designed to unpack some of the detail on the late breaking results of the AMP trial. They will delve more deeply into how well the VRC01 antibody protected WSM and MSM from HIV acquisition and how this will inform future antibody mediated prevention trials in the future.

RT03.01 History of VRC01 – Derivation and preclinical studies
John Mascola, National Institutes of Health, United States
RT03.02 Who took part in AMP and how did it go for them?
Srilatha Edupuganti, Emory Vaccine Center, United States
Nyaradzo MGODI, University of Zimbabwe College of Health Sciences, Zimbabwe

RT03.03 Study design of AMP
Peter GILBERT, Fred Hutchinson Cancer Research Center, United States
RT03.04 Relationship between ID50 and acquisition
Lynn MORRIS, National Institute for Communicable Diseases, South Africa

RT03.05 What does this mean for antibody mediated prevention in the future?
Lawrence Corey, Fred Hutchinson Cancer Research Center, United States
RT03.06 Panel discussion
Georgia TOMARAS, Duke University, United States
Lynn MORRIS, National Institute for Communicable Diseases, South Africa
John Mascola, National Institutes of Health, United States
Srilatha Edupuganti, Emory Vaccine Center, United States
Peter GILBERT, Fred Hutchinson Cancer Research Center, United States
Lawrence Corey, Fred Hutchinson Cancer Research Center, United States
Myron Cohen, UNC School of Medicine, United States
Michel NUSSENZWEIG, The Rockefeller University, United States